📄 BRAVEHEART BIO, INC. ($BRVE)

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor in-licensed from Jiangsu Hengrui Pharmaceuticals, designed to address limitations of existing treatments. The company aims to improve treatment options by enhancing speed of onset, depth of gradient response, systolic safety, and reducing prescribing complexity. Key risk: We are a clinical-stage biopharmaceutical company with a limited operating history, have incurred significant operating losses since inception, and anticipate continued losses; we may never achieve profitability. Lockup: 180 days

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor in-licensed from Jiangsu Hengrui Pharmaceuticals, designed to address limitations of existing treatments. The company aims to improve treatment options by enhancing speed of onset, depth of gradient response, systolic safety, and reducing prescribing complexity.